Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons from experimental APS models

Y Shoenfeld1, L Ziporen

  • 1Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.

Lupus
|November 14, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Clinical and experimental immunology·2003
Same author

Antiphospholipid antibodies in a heterogeneous group of patients: experience from a central laboratory.

Clinical rheumatology·2002
Same author

Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome.

Lupus·1999
Same author

A mouse model for heparin-induced thrombocytopenia.

Seminars in hematology·1999
Same author

Anti-phospholipid syndrome: from patient's bedside to experimental animal models and back to the patient's bedside.

Hematology and cell therapy·1998
Same author

Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

Blood·1998
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Animal models demonstrate that anticardiolipin (aCL) antibodies cause antiphospholipid syndrome (APS) complications, including pregnancy loss, kidney issues, and neurological problems. These models are crucial for understanding APS pathogenesis.

Area of Science:

  • Immunology
  • Pathology
  • Rheumatology

Background:

  • Antiphospholipid syndrome (APS) is a multisystemic autoimmune disease characterized by recurrent thrombosis and pregnancy complications.
  • Anticardiolipin (aCL) antibodies and antiphospholipid antibodies (aPL) are key diagnostic markers for APS.
  • Existing animal models have provided insights into APS, but further research is needed to fully elucidate disease mechanisms.

Purpose of the Study:

  • To investigate the pathogenicity of anticardiolipin (aCL) antibodies in various manifestations of experimental antiphospholipid syndrome (APS).
  • To evaluate the role of aCL antibodies and beta2GPI in inducing APS clinical features in animal models.
  • To explore the potential of using peripheral blood lymphocytes (PBLs) from APS patients to induce APS in immunodeficient mice.

Main Methods:

Related Experiment Videos

  • Immunization of animals with aCL antibodies or beta2GPI to induce experimental APS.
  • Assessment of clinical manifestations including fetal loss, thrombocytopenia, and neurological/behavioral impairments.
  • Utilizing SCID mice engrafted with PBLs from APS patients to study disease transmission.
  • Establishing an in vivo model for thrombus formation to assess aPL pathogenicity in thrombosis.
  • Histological examination of affected tissues from animal models and APS patients.

Main Results:

  • Animals immunized with aCL or beta2GPI developed hallmark APS manifestations, including fetal loss, thrombocytopenia, and neurological dysfunction.
  • Elevated levels of antiphospholipid antibodies (aPL) were observed in affected animals.
  • PBLs from APS patients induced renal dysfunction in SCID mice, indicating a transferable component of the disease.
  • A novel in vivo model confirmed the pathogenicity of aPL in APS-associated thrombosis.
  • Histopathology revealed thrombotic changes with mild inflammation as a common mechanism in both animal models and human APS.

Conclusions:

  • Animal models successfully replicate key clinical and pathological features of antiphospholipid syndrome (APS).
  • Anticardiolipin (aCL) antibodies and associated cofactors play a direct pathogenic role in APS complications.
  • These experimental models are valuable tools for understanding APS pathogenesis and developing therapeutic strategies.